233 related articles for article (PubMed ID: 23429085)
1. Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E.
Mukamoto M; Maeda H; Kohda T; Nozaki C; Takahashi M; Kozaki S
Jpn J Infect Dis; 2013; 66(1):46-50. PubMed ID: 23429085
[TBL] [Abstract][Full Text] [Related]
2. Characterization of neutralizing mouse-human chimeric and shuffling antibodies against botulinum neurotoxin A.
Mukamoto M; Maeda H; Kohda T; Nozaki C; Takahashi M; Kozaki S
Microbiol Immunol; 2012 Nov; 56(11):748-55. PubMed ID: 22938032
[TBL] [Abstract][Full Text] [Related]
3. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
4. Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B.
Matsumura T; Amatsu S; Misaki R; Yutani M; Du A; Kohda T; Fujiyama K; Ikuta K; Fujinaga Y
Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32392791
[TBL] [Abstract][Full Text] [Related]
5. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
[TBL] [Abstract][Full Text] [Related]
6. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
7. Production and characterization of a neutralizing antibody against botulinum neurotoxin A.
Xiong X; Lv S; Fu C; Li L; Sun Z; Han X; Zhang W
J Immunol Methods; 2020 Dec; 487():112871. PubMed ID: 33007319
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.
Sharma R; Zhao H; Al-Saleem FH; Ubaid AS; Puligedda RD; Segan AT; Lindorfer MA; Bermudez R; Elias M; Adekar SP; Simpson LL; Taylor RP; Dessain SK
Mol Immunol; 2014 Feb; 57(2):247-54. PubMed ID: 24184879
[TBL] [Abstract][Full Text] [Related]
9. Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.
Ruwona TB; Xu H; Li J; Diaz-Arévalo D; Kumar A; Zeng M; Cui Z
Hum Vaccin Immunother; 2016 May; 12(5):1188-92. PubMed ID: 26837242
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody.
Derman Y; Selby K; Miethe S; Frenzel A; Liu Y; Rasetti-Escargueil C; Avril A; Pelat T; Urbain R; Fontayne A; Thullier P; Sesardic D; Lindström M; Hust M; Korkeala H
Toxins (Basel); 2016 Sep; 8(9):. PubMed ID: 27626446
[TBL] [Abstract][Full Text] [Related]
11. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B.
Yang GH; Kim KS; Kim HW; Jeong ST; Huh GH; Kim JC; Jung HH
Toxicon; 2004 Jul; 44(1):19-25. PubMed ID: 15225558
[TBL] [Abstract][Full Text] [Related]
13. Botulinum neurotoxins and botulism: a novel therapeutic approach.
Thanongsaksrikul J; Chaicumpa W
Toxins (Basel); 2011 May; 3(5):469-88. PubMed ID: 22069720
[TBL] [Abstract][Full Text] [Related]
14. In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH).
Bakherad H; Mousavi Gargari SL; Rasooli I; Rajabibazl M; Mohammadi M; Ebrahimizadeh W; Safaee Ardakani L; Zare H
Mol Biotechnol; 2013 Oct; 55(2):159-67. PubMed ID: 23666874
[TBL] [Abstract][Full Text] [Related]
15. A natural human IgM antibody that neutralizes botulinum neurotoxin in vivo.
Adekar SP; Al-Saleem FH; Elias MD; Rybinski KA; Simpson LL; Dessain SK
Hybridoma (Larchmt); 2008 Apr; 27(2):65-9. PubMed ID: 18642670
[TBL] [Abstract][Full Text] [Related]
16. Production of serotype C specific and serotype C/D generic monoclonal antibodies using recombinant H(C) and H(N) fragments from Clostridium botulinum neurotoxin types C(1) and D.
Curran RM; Fringuelli E; Graham D; Elliott CT
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):1-10. PubMed ID: 19233482
[TBL] [Abstract][Full Text] [Related]
17. A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes.
Garcia-Rodriguez C; Razai A; Geren IN; Lou J; Conrad F; Wen WH; Farr-Jones S; Smith TJ; Brown JL; Skerry JC; Smith LA; Marks JD
Toxins (Basel); 2018 Mar; 10(3):. PubMed ID: 29494481
[TBL] [Abstract][Full Text] [Related]
18. Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors.
Yu YZ; Guo JP; An HJ; Zhang SM; Wang S; Yu WY; Sun ZW
Vaccine; 2013 May; 31(20):2427-32. PubMed ID: 23583890
[TBL] [Abstract][Full Text] [Related]
19. Development and Characterization of Monoclonal Antibodies to Botulinum Neurotoxin Type E.
Bever CS; Scotcher M; Cheng LW; Hnasko RM; Stanker LH
Toxins (Basel); 2019 Jul; 11(7):. PubMed ID: 31337022
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin.
Garcia-Rodriguez C; Geren IN; Lou J; Conrad F; Forsyth C; Wen W; Chakraborti S; Zao H; Manzanarez G; Smith TJ; Brown J; Tepp WH; Liu N; Wijesuriya S; Tomic MT; Johnson EA; Smith LA; Marks JD
Protein Eng Des Sel; 2011 Mar; 24(3):321-31. PubMed ID: 21149386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
